Autologous bone marrow-derived mesenchymal stem cells seeded on a 3D scaffold in treatment of knee cartilage defects. Prospective open-label study to assess safety and feasibility
Latest Information Update: 22 Mar 2022
Price :
$35 *
At a glance
- Drugs Mesenchymal stem cell therapy (Primary)
- Indications Cartilage disorders; Knee injuries
- Focus Adverse reactions; First in man
- Sponsors Bioinova
- 19 Mar 2022 Status changed from recruiting to completed.
- 24 Feb 2020 Planned End Date changed from 21 May 2021 to 21 Jul 2021.
- 27 Dec 2018 New trial record